Fezolinetant may reduce VMS frequency, improve QoL in postmenopausal women
07 Apr 2021
byElaine Soliven
Postmenopausal women with moderate or severe vasomotor symptoms (VMS), such as hot flashes and/or night sweats, who received fezolinetant were more likely to experience reduced VMS frequency and better health-related quality of life (QoL) than those on placebo, according to the secondary analysis of VESTA* study.